These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8743977)

  • 1. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
    Malisza KL; Hasinoff BB
    Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells.
    Malisza KL; McIntosh AR; Sveinson SE; Hasinoff BB
    Free Radic Res; 1996 Jan; 24(1):9-18. PubMed ID: 8747888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
    Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
    Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of dexrazoxane.
    Hochster HS
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
    Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
    Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
    Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane use in the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D; Wu X
    Free Radic Biol Med; 2003 Dec; 35(11):1469-79. PubMed ID: 14642395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
    Langer SW; Sehested M; Jensen PB
    Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.